Source: Eur Respir J, 58 (3) 2004133; 10.1183/13993003.04133-2020
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Michael F. Morris, Yash Pershad, Paul Kang, Lauren Ridenour, Ben Lavon, Maarten Lanclus, Rik Godon, Jan De Backer, Marilyn K. Glassberg. Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease. Eur Respir J, 58 (3) 2004133; 10.1183/13993003.04133-2020

Member's Comments

No comment yet.

Related content which might interest you: Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients. Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis. Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Short-term dynamic lung function and predictors of lung function decline in systemic sclerosis-related interstitial lung disease Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Simultaneous analysis of clinical markers for predicting increased lung function fluctability in stable asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 The use of non-invasive stroke volume measurement to assess treatment response in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Determinants and prognostic value of kidney disease in pulmonary arterial hypertension Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Predicting prognosis of lung function decline in IPF using gene expression in peripheral blood mononuclear cells Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease Source: Eur Respir J, 52 (3) 1801015; 10.1183/13993003.01015-2018 Year: 2018 Relationship of airway structural changes and lung function abnormalities with blood and BAL biomarkers in asthma Source: International Congress 2019 – Lung function evaluation and prognosis of airway diseases Year: 2019 Impact of long-term oxygen therapy on systemic inflammation, morphological changes of red blood cells, pulmonary hemodynamics and diaphragm function in patients with chronic obstructive pulmonary disease. Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Low-t3 state a crucial biomarker in determining NIV failure and outcome in pulmonary patient? Source: Annual Congress 2011 - Mechanical ventilation and weaning Year: 2011 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 High-sensitive troponin T as a new biomarker and an indicator of disease severity in patients with pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Prognostic relevance of changes in exercise parameters in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Source: Eur Respir J , 49 (2) 1602524; DOI: 10.1183/13993003.02524-2016 Year: 2017